By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1111 Main Street
Suite 660
Vancouver  Washington  98660  U.S.A.
Phone: 360-980-8524 Fax: 360-980-8549



Company News
Data Presented At CROI Show CytoDyn (CYDY)’s Pro 140 As A Single Agent Provided Maximal Virologic Suppression In HIV Patients For Nearly Two Years 2/16/2017 8:01:10 AM
CMC Biologics Enters Into Manufacturing Agreement With CytoDyn (CYDY) 2/15/2017 8:33:22 AM
Two-Year Update From CytoDyn (CYDY)’s PRO 140 Monotherapy Study In HIV To Be Featured In Two Events At CROI 2017 2/14/2017 10:58:06 AM
CytoDyn (CYDY) Strengthens Executive Management With Appointment Of Anthony D. Caracciolo As Executive Chairman 1/30/2017 7:08:53 AM
CytoDyn (CYDY) Release: Biotech Files For Breakthrough Therapy Designation With The FDA For PRO 140 In HIV Therapy 1/11/2017 7:07:50 AM
CytoDyn (CYDY) Announces Investment Community Conference Call For January 5, 2017 1/4/2017 7:17:32 AM
CytoDyn (CYDY) Reports Treatment Of First Several Patients With PRO 140 In Its Phase III Monotherapy Trial For HIV 12/12/2016 7:21:42 AM
CytoDyn (CYDY)’s Two-Year Update On Its PRO 140 Monotherapy Study In HIV Accepted At CROI 2017 11/16/2016 7:53:09 AM
CytoDyn (CYDY) Announces Webcast Of Investment Community Presentation On November 11 11/9/2016 7:27:27 AM
CytoDyn (CYDY) Files Protocol For Extended Access To PRO 140 For Patients Who Reach The End Of PRO 140 Pivotal Phase III Trial 10/24/2016 7:52:00 AM